DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In agilon health To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in agilon health between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) and reminds investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly issued guidance for 2025 that they knew or should have known was not going to be achieved, given material industry headwinds of which they were aware; (2) Defendants materially overstated the immediate positive financial impact from “strategic actions” taken by agilon to reduce risk; and (3) as a result, defendants’ statements about agilon’s business, operations, and prospects were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On August 4, 2025, agilon health issued a press release entitled "agilon health Reports Second Quarter 2025 Results." Commenting on the results, agilon health's Executive Chair stated that "as we progressed through this transition year, it's become clear that the industry headwinds are more acute than previously expected[.]" Further, the release announced that the company was "suspending its previously issued full-year 2025 financial guidance and related assumptions."

On this news, agilon health's stock fell 51.5% on August 5, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding agilon health’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the agilon health class action, go to www.faruqilaw.com/AGL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.